European Journal of Dermatology
MENUMedical costs of surgical intervention for hospitalized patients with neurofibromatosis 1 in Japan Volume 30, issue 5, September-October 2020
Tables
1 Department of Dermatology, Fukuoka University School of Medicine, Fukuoka, Japan
2 Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan
- DOI : 10.1684/ejd.2020.3869
- Page(s) : 618-20
- Published in: 2020
Diffuse plexiform neurofibroma (dNF), one of the clinical manifestations of neurofibromatosis 1 (NF1), may result in the development of a malignant peripheral nerve sheath tumour, disfigurement, and life-threatening massive intratumour haemorrhage [1]. Although various treatments such as mitogen-activated protein kinase (MEK) inhibitors for neurofibromas in patients with NF1 have been investigated in clinical trials [2-5], surgical resection still remains the primary treatment.However, the removal [...]